Skip to search formSkip to main contentSkip to account menu

ABT-450

Known as: ABT 450, ABT450 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Macrocyclic Compounds

Narrower (1)

paritaprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans
Paritaprevir (also known as ABT-450), a potent NS3-4A serine protease inhibitor [identified by AbbVie (North Chicago, IL) and… 
Review
2015
Review
2015
ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus
Introduction: The global prevalence of chronic hepatitis C virus (HCV) is estimated to be 80 – 115 million and currently viremic… 
Review
2015
Review
2015
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients
Chronic hepatitis C (CHC) constitutes a major health concern. Hepatitis C virus eradication by antiviral treatment can markedly… 
Highly Cited
2014
Highly Cited
2014
Therapy of hepatitis C--back to the future.
A book on hepatitis C would read like a marriage of an Orson Welles mystery and a Shakespearean play — awash in enigma, tragedy… 
Review
2014
Review
2014
New antiviral agents for the treatment of hepatitis C: ABT-450
Introduction: Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non… 
2014
2014
HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?
2014
2014
Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
Whether concomitant HIV antiretroviral therapy (ART) affects the safety and efficacy of interferon‐free HCV therapies or whether… 
Review
2014
Review
2014
NS 3 protease inhibitors for treatment of chronic hepatitis C : Efficacy and safety
A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a… 
Review
2013
Review
2013
Sofosbuvir and ABT-450: terminator of hepatitis C virus?
Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C… 
2011
2011
1229 GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF NS3 VARIANTS SELECTED IN HCV-INFECTED PATIENTS TREATED WITH ABT-450
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)